Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory DisordersDavid Harrison, Alan P. Watt, Andy Billinton et al.|Journal of Medicinal Chemistry|2023Cited by 62
Discovery of a series of ester-substituted NLRP3 inflammasome inhibitorsDavid Harrison, Alan P. Watt, Anna Cierpich et al.|Bioorganic & Medicinal Chemistry Letters|2020Cited by 30
Discovery and Optimization of Triazolopyrimidinone Derivatives as Selective NLRP3 Inflammasome InhibitorsDavid Harrison, Alan P. Watt, Mark G. Bock et al.|ACS Medicinal Chemistry Letters|2022Cited by 23
Target Cell Activation of a Structurally Novel NOD-Like Receptor Pyrin Domain-Containing Protein 3 Inhibitor NT-0796 Enhances PotencyPamela J. Smolak, Christopher A. Gabel, MyTrang Nguyen et al.|Journal of Pharmacology and Experimental Therapeutics|2024Cited by 13
Pharmacological Analysis of NLRP3 Inflammasome Inhibitor Sodium [(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl][(1-methyl-1<i>H</i>-pyrazol-4-yl)({[(2<i>S</i>)-oxolan-2-yl]methyl})sulfamoyl]azanide in Cellular and Mouse Models of Inflammation Provides a Translational FrameworkJohn R. Doedens, Christopher A. Gabel, Pamela J. Smolak et al.|ACS Pharmacology & Translational Science|2024Cited by 8